Home / Psoriasis / Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis

Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis

Brief Summary:
Phase I clinical trial to evaluate safety of FURESTEM-CD Inj. in patients with moderate to severe in plaque-type psoriasis injection for 4weeks.

Condition or disease Intervention/treatment Phase
Psoriasis Biological: FURESTEM-CD Inj. Phase 1

Detailed Description:

This is a phase 1, single center, randomized, open label, study of safety of FURESTEM-CD Inj. in subjects with moderate to severe plaque psoriasis.

Approximately 9~18 subjects will be administrated FURESTEM-CD Inj.

FURESTEM-CD Inj. is composed of allogeneic hUCB-MSC(human Umbilical Cord Blood derived-Mesenchymal Stem cell). hUCB-MSCs are mesenchymal stem cells from umbilical cord blood. Mesenchymal stem cells are well-known for immunosuppression, anti-inflammatory ability and capable of differentiating into a wide range of cell types. Therefore, FURSTEM-CD Inj. has huge possibility as cell therapy products for plaque-type Psoriasis patients.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment :9 participants
Intervention Model:Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title:Phase 1 Clinical Trial to Evaluate the Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis.
Actual Study Start Date :January 17, 2018
Estimated Primary Completion Date :December 2021
Estimated Study Completion Date :December 2021
Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

U.S. FDA Resources

About

Check Also

Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis

Study Description Go to  Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts …

Leave a Reply

Your email address will not be published. Required fields are marked *